ArticleScience immunology2023
Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein.
Open access · bronzeAbstract read
In one paragraph
Article in Science immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
16.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 85 citations in OpenAlex.
- An IgG-like fusion protein comprising an anti-spike S2 antibody and ACE2 exhibits potent and broad neutralization against SARS-CoV-2 and variants of concern.Antibody therapeutics · 2026Article
- Article
- Structural basis of diverse antibody recognition of conserved coronavirus spike S2 epitopes that contribute to protective immunity.bioRxiv : the preprint server for biology · 2026Article
- Dissociation kinetics and avidity gate SARS-CoV-2 neutralization by HR2 stem helix antibodies.bioRxiv : the preprint server for biology · 2026Article
- Structural and functional characterization of a conserved cryptic epitope on SARS-CoV-2 spike S2 subunit.PLoS pathogens · 2026Article
- Article
- SARS-CoV-2 Omicron infection reveals imprinted antibody responses in the absence of vaccination.iScience · 2026Article
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- Article
- Human antibodies against West Nile and related orthoflaviviruses.bioRxiv : the preprint server for biology · 2026Article
- SARS-CoV-2 fusion-peptide-directed antibodies are elicited by natural infection and can mediate broad sarbecovirus neutralization.Cell reports · 2026Article
- The buried S2 apex of SARS-CoV-2 spike elicits an immunodominant germline-restricted public antibody response.bioRxiv : the preprint server for biology · 2026Article
- Heterologous betacoronavirus spike immunization in nonhuman primates elicits cross-reactive antibodies that neutralize both sarbeco- and merbecoviruses.bioRxiv : the preprint server for biology · 2026Article
- Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses.Research square · 2025Article
- Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches.Emerging microbes & infections · 2025Article
- Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolution.Nature communications · 2025Article
- Unconventional linkers facilitate potent stabilized coronavirus stem antibody responses following nanoparticle vaccination.bioRxiv : the preprint server for biology · 2025Article
- Human Coronavirus HKU1 Neutralizing Monoclonal Antibodies Target Diverse Epitopes Within and Around the TMPRSS2 Receptor Binding Site.bioRxiv : the preprint server for biology · 2025Article
- Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses.bioRxiv : the preprint server for biology · 2025Article
- Signatures of omicron-like adaptation in early SARS-CoV-2 variants and chronic infection.Cell reports · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
46 authors at 15 institutions in 6 countries.
Filippo BianchiniInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-0746-7629
Virginia CrivelliInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0003-2494-7242
Morgan E AbernathyDepartment of Biology, Stanford University, Stanford, CA, USA.
Concetta GuerraInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0001-5597-6885
Martin PalusInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic.ORCID 0000-0002-4279-7092
Jonathan MuriInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Harold MarcotteDepartment of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.ORCID 0000-0002-7168-349X
Antonio PirallaMicrobiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID 0000-0002-6062-2579
Mattia PedottiInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0003-1370-9505
Raoul De GasparoInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-7934-8290
Luca SimonelliInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Milos MatkovicInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-4872-1996
Chiara ToscanoInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-0309-946X
Maira BiggiogeroClinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.
Veronica CalvarusoClinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.
Pavel SvobodaInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic.ORCID 0000-0002-2180-3174
Tomás Cervantes RincónInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-6355-6781
Tommaso FavaInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0003-2767-5641
Lucie PodešvováInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0003-1054-2252
Akanksha A ShanbhagInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-1676-2478
Andrea CeloriaInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-6107-8296
Jacopo SgrignaniInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Michal StefanikVeterinary Research Institute, Brno, Czech Republic.ORCID 0000-0003-4390-7780
Vaclav HönigInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic.ORCID 0000-0003-0469-4604
Veronika PranclovaInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic.ORCID 0000-0003-1660-1372
Tereza MichalcikovaCzech Centre of Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.ORCID 0000-0002-0172-2254
Jan ProchazkaCzech Centre of Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.
Giuditta GuerriniEuropean Commission, Joint Research Centre (JRC), Ispra Italy.ORCID 0000-0002-1446-0556
Dora MehnEuropean Commission, Joint Research Centre (JRC), Ispra Italy.ORCID 0000-0003-3482-2996
Annalisa CiabattiniLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.ORCID 0000-0002-4585-7783
Hassan AbolhassaniDepartment of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.ORCID 0000-0002-4838-0407
David JarrossayInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-0924-6395
Mariagrazia UguccioniInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-9570-7011
Donata MedagliniLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Qiang Pan-HammarströmDepartment of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.ORCID 0000-0003-1990-8804
Luigi CalzolaiEuropean Commission, Joint Research Centre (JRC), Ispra Italy.ORCID 0000-0002-8474-7974
Daniel FernandezSarafan ChEM-H Macromolecular Structure Knowledge Center, Stanford University, Stanford, CA, USA.ORCID 0000-0002-6221-152X
Fausto BaldantiMicrobiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID 0000-0002-3358-8969
Alessandra Franzetti-PellandaClinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.ORCID 0000-0002-0769-2500
Christian GarzoniInternal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.ORCID 0000-0002-0832-2376
Radislav SedlacekCzech Centre of Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.ORCID 0000-0002-3352-392X
Daniel RuzekInstitute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic.ORCID 0000-0003-4655-2380
Luca VaraniInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0002-0963-0987
Andrea CavalliInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0003-4063-4502
Christopher O BarnesDepartment of Biology, Stanford University, Stanford, CA, USA.ORCID 0000-0003-2754-5951
Davide F RobbianiInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID 0000-0001-7379-3484
Università della Svizzera italiana · CHClinica Luganese Moncucco · CHCzech Academy of Sciences, Institute of Molecular Genetics · CZJoint Research Centre · ITKarolinska Institutet · SEVeterinary Research Institute · CZStanford University · USUniversity of Siena · ITChan Zuckerberg Initiative (United States) · USMasaryk University · CZPoliclinico San Matteo Fondazione · ITSIB Swiss Institute of Bioinformatics · CHUniversity of Pavia · ITUniversity of South Bohemia in České Budějovice · CZUniversity of Veterinary Sciences Brno · CZ
Funding
A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI KEITH O HODGSON · 2020 to 2026
$43.3MUnderstanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2014 to 2023
$26.0MUniversity of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3MVirology CoreP01AI138938 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2018 to 2022
$8.4MNIAID NIH HHS P01 AI138938NIAID NIH HHS U01 AI151698NIAID NIH HHS U19 AI111825NIGMS NIH HHS P30 GM133894Swiss National Science Foundation 196866
Abstract
Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued development of immunotherapies and vaccine immunogens resilient to viral evolution is therefore necessary. Using coldspot-guided antibody discovery, a screening approach that focuses on portions of the virus spike glycoprotein that are both functionally relevant and averse to change, we identified human neutralizing antibodies to highly conserved viral epitopes. Antibody fp.006 binds the fusion peptide and cross-reacts against coronaviruses of the four genera, including the nine human coronaviruses, through recognition of a conserved motif that includes the S2' site of proteolytic cleavage. Antibody hr2.016 targets the stem helix and neutralizes SARS-CoV-2 variants. Antibody sd1.040 binds to subdomain 1, synergizes with antibody rbd.042 for neutralization, and, similar to fp.006 and hr2.016, protects mice expressing human angiotensin-converting enzyme 2 against infection when present as a bispecific antibody. Thus, coldspot-guided antibody discovery reveals donor-derived neutralizing antibodies that are cross-reactive with Orthocoronavirinae, including SARS-CoV-2 variants.
Indexed as
Antibodies, NeutralizingCOVID-19AnimalsAntibodies, ViralEpitopesHumansMiceNeutralization TestsSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.